PharmExec Direct - Pharmaceutical Executive

ADVERTISEMENT

PharmExec Direct

Pharma Trials Heading South

May 21, 2009

Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials.

No Such Thing as Free Drugs?

May 21, 2009

New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.?

Wrangling Over Research Results

May 21, 2009

Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.

A Review of Tafas v. Doll

May 21, 2009

Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules.

New Study Reveals Distribution Trends in Drug Sampling

January 9, 2008

Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees.

Data Mining Companies Score Legal Win in Maine

January 9, 2008

IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms.

BioMS Medical Signs $500 Million Agreement with Lilly

January 9, 2008

Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS.

Preemption Gets Boost from Bush

December 12, 2007

State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer?

BMS Cuts Bloated Manufacturing Arm to Bolster R&D

December 12, 2007

Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing.

ADVERTISEMENT

Click here